ONIOM and FMO-EDA study of metabotropic glutamate receptor 1: Quantum insights into the allosteric binding site

2018 ◽  
Vol 118 (15) ◽  
pp. e25617 ◽  
Author(s):  
Paweł Śliwa ◽  
Rafał Kurczab ◽  
Andrzej J. Bojarski
Keyword(s):  
Binding Site ◽  
Glutamate Receptor ◽  
Metabotropic Glutamate Receptor ◽  
Metabotropic Glutamate ◽  
Metabotropic Glutamate Receptor 1

scholarly journals Amino Acid Mutagenesis of the Ligand Binding Site and the Dimer Interface of the Metabotropic Glutamate Receptor 1

2002 ◽  
Vol 278 (6) ◽  
pp. 4314-4321 ◽  
Author(s):  
Toshihiro Sato ◽  
Yoshimi Shimada ◽  
Naoko Nagasawa ◽  
Shigetada Nakanishi ◽  
Hisato Jingami
Keyword(s):  
Amino Acid ◽  
Ligand Binding ◽  
Binding Site ◽  
Glutamate Receptor ◽  
Metabotropic Glutamate Receptor ◽  
Ligand Binding Site ◽  
Dimer Interface ◽  
Metabotropic Glutamate ◽  
Metabotropic Glutamate Receptor 1 ◽  
Amino Acid Mutagenesis

scholarly journals Metabotropic glutamate receptor 1 is associated with unfavorable prognosis in ER-negative and triple-negative breast cancer

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Anna E. M. Bastiaansen ◽  
A. Mieke Timmermans ◽  
Marcel Smid ◽  
Carolien H. M. van Deurzen ◽  
Esther S. P. Hulsenboom ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Protein Expression ◽  
Glutamate Receptor ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Metabotropic Glutamate Receptor ◽  
Metabotropic Glutamate ◽  
Metabotropic Glutamate Receptor 1 ◽  
Novel Target ◽  
Cancer Tissues

AbstractNew therapies are an urgent medical need in all breast cancer subgroups. Metabotropic glutamate receptor 1 (mGluR1) is suggested as a potential new molecular target. We examined the prevalence mGluR1 expression in different clinically relevant breast cancer subgroups and determined its association with prognosis. In this retrospective cohort, 394 consecutive primary breast cancer tissues were incorporated into a tissue microarray and immunohistochemically stained for mGluR1. The prevalence of mGluR1 protein expression in different breast cancer subgroups was evaluated and correlated with metastasis-free survival (MFS) and overall survival (OS). In total, 56% (n = 219) breast cancer tissues had mGluR1 expression. In estrogen receptor (ER)-negative tumors, 31% (n = 18/58) had mGluR1 expression that was significantly associated with MFS (HR 5.00, 95% CI 1.03–24.35, p = 0.046) in multivariate analysis, independently from other prognostic factors. Of the 44 triple-negative breast cancer (TNBC), 25% (n = 11) expressed mGluR1. mGluR1 expression in TNBC was significantly associated with shorter MFS (HR 8.60, 95% CI 1.06–20.39, p = 0.044) and with poor OS (HR 16.07, 95% CI 1.16–223.10, p = 0.039). In conclusion, mGluR1 is frequently expressed in breast cancer. In ER-negative breast cancer and in TNBC mGluR1 protein expression is an unfavorable prognostic marker. This study provides rationale to explore mGluR1 as a novel target for breast cancer treatment, especially for the more aggressive TNBC.

scholarly journals Autosomal-Recessive Congenital Cerebellar Ataxia Is Caused by Mutations in Metabotropic Glutamate Receptor 1

2012 ◽  
Vol 91 (3) ◽  
pp. 553-564 ◽  
Author(s):  
Velina Guergueltcheva ◽  
Dimitar N. Azmanov ◽  
Dora Angelicheva ◽  
Katherine R. Smith ◽  
Teodora Chamova ◽  
...  
Keyword(s):  
Cerebellar Ataxia ◽  
Glutamate Receptor ◽  
Autosomal Recessive ◽  
Metabotropic Glutamate Receptor ◽  
Metabotropic Glutamate ◽  
Metabotropic Glutamate Receptor 1

scholarly journals Immunolocalization of the mGluR1b Splice Variant of the Metabotropic Glutamate Receptor 1 at Parallel Fiber-Purkinje Cell Synapses in the Rat Cerebellar Cortex

2000 ◽  
Vol 74 (3) ◽  
pp. 1301-1309 ◽  
Author(s):  
José María Mateos ◽  
Rocío Benítez ◽  
Izaskun Elezgarai ◽  
Jon Jatsu Azkue ◽  
Esther Lázaro ◽  
...  
Keyword(s):  
Purkinje Cell ◽  
Glutamate Receptor ◽  
Cerebellar Cortex ◽  
Splice Variant ◽  
Metabotropic Glutamate Receptor ◽  
Parallel Fiber ◽  
Metabotropic Glutamate ◽  
Metabotropic Glutamate Receptor 1

scholarly journals The non-competitive metabotropic glutamate receptor-1 antagonist CPCCOEt inhibits the in vitro growth of human melanoma

2007 ◽  
Author(s):  
Helga Haas ◽  
Roswitha Pfragner ◽  
Veronika Siegl ◽  
Elisabeth Ingolic ◽  
Elfgard Heintz ◽  
...  
Keyword(s):  
Glutamate Receptor ◽  
Metabotropic Glutamate Receptor ◽  
Human Melanoma ◽  
In Vitro Growth ◽  
Metabotropic Glutamate ◽  
Metabotropic Glutamate Receptor 1

scholarly journals Metabotropic Glutamate Receptor-1 Contributes to Progression in Triple Negative Breast Cancer

PLoS ONE ◽  
2014 ◽  
Vol 9 (1) ◽  
pp. e81126 ◽  
Author(s):  
Malathi Banda ◽  
Cecilia L. Speyer ◽  
Sara N. Semma ◽  
Kingsley O. Osuala ◽  
Nicole Kounalakis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Glutamate Receptor ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Metabotropic Glutamate Receptor ◽  
Metabotropic Glutamate ◽  
Metabotropic Glutamate Receptor 1

scholarly journals Proteomic analysis reveals novel binding partners of metabotropic glutamate receptor 1

2009 ◽  
Vol 108 (6) ◽  
pp. 1515-1525 ◽  
Author(s):  
Anna Francesconi ◽  
Ranju Kumari ◽  
R. Suzanne Zukin
Keyword(s):  
Glutamate Receptor ◽  
Proteomic Analysis ◽  
Metabotropic Glutamate Receptor ◽  
Metabotropic Glutamate ◽  
Binding Partners ◽  
Metabotropic Glutamate Receptor 1

scholarly journals 11C-LY2428703, a positron emission tomographic radioligand for the metabotropic glutamate receptor 1, is unsuitable for imaging in monkey and human brains

2013 ◽  
Vol 3 (1) ◽  
pp. 47 ◽  
Author(s):  
Paolo Zanotti-Fregonara ◽  
Vanessa N Barth ◽  
Sami S Zoghbi ◽  
Jeih-San Liow ◽  
Eric Nisenbaum ◽  
...  
Keyword(s):  
Glutamate Receptor ◽  
Metabotropic Glutamate Receptor ◽  
Positron Emission Tomographic ◽  
Metabotropic Glutamate ◽  
Positron Emission ◽  
Metabotropic Glutamate Receptor 1 ◽  
Human Brains
Sign in / Sign up

Export Citation Format

Share Document